Glycomimetics Inc (GLYC) 8.60 $GLYC Will TrovaGene

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Glycomimetics Inc (GLYC) 8.60 $GLYC

Will TrovaGene (TROV) Pull an Earnings Surprise in Q2?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:11AM CDT
TrovaGene Inc. (TROV) is expected to release second-quarter 2016 results on Aug 4.
ZTS: 50.43 (-0.04), TROV: 5.58 (-0.05), ANIP: 60.58 (-0.02), GLYC: 8.60 (+0.25)

Inogen (INGN) Q2 Earnings: Can the Stock Pull a Surprise?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 8:54AM CDT
Inogen Inc. (INGN) is scheduled to report second-quarter 2016 results on Aug 4.
ZTS: 50.43 (-0.04), ANIP: 60.58 (-0.02), INGN: 52.88 (-0.86), GLYC: 8.60 (+0.25)

Pacific Biosciences (PACB) Q2 Earnings: What's in Store?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 8:52AM CDT
Pacific Biosciences of California Inc. (PACB) is scheduled to report second-quarter 2016 results on Aug 4.
ZTS: 50.43 (-0.04), PACB: 8.57 (+0.02), ANIP: 60.58 (-0.02), GLYC: 8.60 (+0.25)

Iron Mountain (IRM) to Post Q2 Earnings: What to Expect?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 8:50AM CDT
Iron Mountain Inc. (IRM), a leading provider of data protection and information management services, is set to release its second-quarter 2016 results on Aug 4.
CTAS: 107.17 (-0.10), IRM: 40.99 (-0.22), GLYC: 8.60 (+0.25), SLCA: 33.16 (-1.31)

Can Cerner (CERN) Spring a Surprise This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 3:45PM CDT
Cerner Corporation (CERN) is expected to report second-quarter 2016 results on Aug 2.
ANIP: 60.58 (-0.02), GLYC: 8.60 (+0.25), NKTR: 17.73 (+0.44), CERN: 62.24 (-0.15)

Cardinal Health (CAH) Q4 Earnings: Disappointment in Store?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 3:01PM CDT
Cardinal Health Inc. (CAH) is set to report fourth-quarter fiscal 2016 earnings results on Aug 2.
ANIP: 60.58 (-0.02), CAH: 82.67 (-0.93), GLYC: 8.60 (+0.25), NKTR: 17.73 (+0.44)

Can PerkinElmer (PKI) Pull a Surprise this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:24AM CDT
PerkinElmer Inc. is expected to report second-quarter 2016 results on Aug 4.
ANIP: 60.58 (-0.02), GLYC: 8.60 (+0.25), PKI: 56.87 (-0.05), HUM: 170.55 (-2.00)

Becton, Dickinson (BDX) Q3 Earnings: What's in the Cards?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:01AM CDT
Becton, Dickinson and Company (BDX) is set to report third-quarter fiscal 2016 earnings results on Aug 4.
BDX: 177.04 (+1.04), ANIP: 60.58 (-0.02), GLYC: 8.60 (+0.25), NKTR: 17.73 (+0.44)

New Strong Buy Stocks for July 7th
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 6:33AM CDT
New Strong Buy Stocks for July 7th
BG: 63.05 (-2.79), DRII: 29.75 (-0.43), MUR: 25.60 (-1.83), OMN: 8.77 (-0.70), GLYC: 8.60 (+0.25)

GlycoMimetics (GLYC) Worth Watching: Stock Surges 13.1%
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 7:00AM CDT
GlycoMimetics, Inc. (GLYC) was a big mover last session, as the company's shares rose over 13% on the day.
GLYC: 8.60 (+0.25)

GlycoMimetics Announces Proposed Public Offering of Common Stock
BusinessWire - Thu Jun 16, 3:01PM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC), a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. All of the shares of common stock to be sold in the offering will be offered by GlycoMimetics. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
GLYC: 8.60 (+0.25)

GlycoMimetics' GMI-1271 Yields High Remission Rates and Favorable Tolerability in Phase 1 Portion of Phase 1/2 Clinical Trial for AML
BusinessWire - Fri Jun 10, 5:00AM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced data from the Phase 1 portion of its Phase 1/2 clinical trial of its novel E-selectin antagonist, GMI-1271, combined with induction chemotherapy, in patients with relapsed/refractory acute myeloid leukemia (AML). Dose escalation is complete and a GMI-1271 dose was identified for Phase 2 testing.
GLYC: 8.60 (+0.25)

GlycoMimetics Doses First Patient in Phase 2 Portion of GMI-1271 Clinical Trial in Relapsed/Refractory Acute Myeloid Leukemia
BusinessWire - Mon Jun 06, 8:00AM CDT
GlycoMimetics, Inc. (NASDAQ:GLYC) today announced dosing of the first patient with relapsed/refractory acute myeloid leukemia in the Phase 2 portion of its ongoing Phase 1/2 clinical trial evaluating its novel E-selectin antagonist, GMI-1271, combined with induction chemotherapy.
GLYC: 8.60 (+0.25)

GlycoMimetics to Present at Jefferies 2016 Healthcare Conference
BusinessWire - Thu Jun 02, 8:00AM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that Chief Financial Officer Brian Hahn will provide a company overview at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 at 9:30 a.m. EDT in New York City.
GLYC: 8.60 (+0.25)

Will GlycoMimetics (GLYC) Continue to Surge Higher?
Zacks Equity Research - Zacks Investment Research - Thu May 26, 8:39AM CDT
As of late, it has definitely been a great time to be an investor in GlycoMimetics, Inc. (GLYC).
GLYC: 8.60 (+0.25)

The 3 Best Developmental Stage Biotech Stocks Surging Now
Maher Syed - Zacks Investment Research - Wed May 25, 5:44PM CDT
These Biotech stocks are small now, but they look set to see significant developments in their various drug candidates.
VTAE: 10.65 (unch), GLYC: 8.60 (+0.25), DMTX: 6.89 (-0.23)

GlycoMimetics Announces Publication of New Preclinical Data with GMI-1271 in Science Translational Medicine
BusinessWire - Wed May 25, 1:00PM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that the peer-reviewed journal, Science Translational Medicine, has published preclinical research in its May 25 issue pointing to a potential clinical application for GMI-1271 in the treatment of breast cancer. The published study details research in an in vivo model that showed the company's drug candidate, GMI-1271, a novel E-selectin antagonist, inhibits breast cancer metastasis.
GLYC: 8.60 (+0.25)

Initial Efficacy Data for GlycoMimetics' GMI-1271 Combined with Chemotherapy in Patients with AML to Be Presented at European Hematology Association 21st Congress
BusinessWire - Thu May 19, 8:30AM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that initial efficacy data from a Phase 1/2 clinical trial on the effects of drug candidate GMI-1271 combined with chemotherapy on patients with acute myeloid leukemia (AML) were accepted as a poster to be presented at the European Hematology Association's 21st Congress, taking place June 9-12 in Copenhagen, Denmark.
GLYC: 8.60 (+0.25)

GlycoMimetics Reports First Quarter 2016 Results
BusinessWire - Wed May 04, 8:00AM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) today reported financial results for the first quarter ended March 31, 2016.
GLYC: 8.60 (+0.25)

GlycoMimetics Data on GMI-1271 Treatment of Acetaminophen-Triggered Liver Toxicity to Be Presented at "Digestive Disease Week" Conference
BusinessWire - Mon Apr 25, 3:30PM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that collaborative research on the effects of its clinical drug candidate GMI-1271 on E-selectin, and acetaminophen- induced liver damage was accepted for an oral presentation at "Digestive Disease Week," the annual meeting of the American Gastroenterological Association, American Association for the Study of Liver Diseases, American Society for Gastrointestinal Endoscopy and the Society for Surgery of the Alimentary Tract. The meeting will take place May 21-24 in San Diego.
GLYC: 8.60 (+0.25)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Carolina Pines Tackles Rural Healthcare Myths on TV

Updated Category News Views 47

Rural Healthcare Battles the Big City Myth Picture this: you're in a tiny town where everyone knows your dog's name, but some think you've got to head to the city for top-notch medical care. That's where Carolina Pines Regional Medical Center steps in. They’ve snagged a spot on 'All Access with Andy Garcia', shining a light on how investments in tech and talent keep...

Continue Reading
Tips for a Dementia-Friendly Thanksgiving Gathering

Updated Category News Views 21

Thanksgiving's supposed to bring families round the table, right? But toss a few knuckleheads together, add a pinch of dementia, and suddenly it's like throwing dice at a craps table. The American Speech-Language-Hearing Association (ASHA) reckons they've got tricks up their sleeve to keep the holiday from unraveling. The Thanksgiving Reality Check The hustle, bustle, and...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 385

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Mining Equipment Market to Surge, Hitting $42.81B by 2033

Updated Category News Views 20

Forecasts on Market Growth: A Robust Climb Ahead Brace yourself because this mining equipment racket is ramping up like you wouldn't believe. Analysts are telling us the market's supposed to roar from a $28.42 billion check in 2026 to a jaw-dropping $42.81 billion come 2033. That's a 6.0% CAGR—a figure that'll catch the eye of anyone not sound asleep at the wheel....

Continue Reading
Ascletis' Preclinical Successes: Future of Obesity Treatment

Updated Category News Views 84

Pharma Giants Eyeing a New Potential Well, it seems the world of pharma is buzzing with Ascletis’ latest developments in the obesity treatment arena. They’ve just showcased some intriguing preclinical data at ObesityWeek® 2026. The standout? A cocktail of advancements that might just put a dent in the obesity epidemic if further studies pan out. ASC30_48: A Daily...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 226

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
Dar Global Expands Jeddah Portfolio with $267M Project

Updated Category News Views 77

Dar Global's Big Jeddah Move: A $267M Bet Alright, let's dive into what Dar Global's been up to in Saudi Arabia. They've just announced a whopping SAR 1 billion development project in Jeddah, bringing an international luxury brand to the city with an exclusive co-branded residential concept. Now that's something to chew on for any investor eyeing the Middle East's real...

Continue Reading
DemandTec Leads the Pack in Retail Pricing Arena

Updated Category News Views 12

DemandTec's Climb to Retail Pricing Stardom The news hitting the streets is that DemandTec's carved out a top spot in QKS Group's SPARK Matrix™ for Intelligent Retail Pricing & Promotion Optimization for 2026. In an industry filled with slick operators and gimmicks, it takes some real chops to stand out. They've clinched this position by rolling out a platform that ties...

Continue Reading
ELEGRP Makes Dyson Supersonic Global Voltage Ready

Updated Category News Views 36

Plugging Into the Future of Travel ELEGRP's latest move brings the Dyson Supersonic Travel hair dryer into the limelight, all decked out with global voltage compatibility. It's like the Swiss Army knife of hair dryers—one minute it’s working on 100V, next it’s flipping over to a juicy 240V, without breaking a sweat. The ALCI Difference: Safety Takes Center Stage...

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading

Top 5 Most Recently Viewed Articles

Steel Dynamics Insider Sell: Key Insights and Future Outlook

Updated Category News Views 91

Understanding Recent Insider Transactions at Steel Dynamics In a noteworthy development, James Stanley Anderson, the Senior Vice President of Steel Dynamics (NASDAQ: STLD), executed a substantial sell-off of shares, raising eyebrows among investors and industry analysts alike. This insider transaction, reported through an SEC filing, includes the sale of 10,000 shares,...

Continue Reading
Final Cash Distributions for iShares Premium Money Market ETF

Updated Category News Views 182

Final Cash Distributions Announced BlackRock Asset Management Canada Limited has recently revealed significant cash distributions for the iShares Premium Money Market ETF. This announcement, which is essential for investors looking to optimize their financial strategies, includes details on the cash distributions that will be made available for unitholders. Distribution...

Continue Reading
Sina Corporation Investors Encouraged to Join Class Action

Updated Category News Views 161

Sina Corporation Investors Encouraged to Join Class Action Attention investors of Sina Corporation (NASDAQ:SINA): If you've experienced significant financial losses related to the company's stock, you have a valuable opportunity to take action. A class action lawsuit has been initiated against Sina and its executives. Understanding the Class Action The lawsuit has been...

Continue Reading
Talisker’s Bralorne Gold Project Shows Thriving Ore Sorting Potential

Updated Category News Views 258

Talisker’s Innovative Approach to Ore Sorting Talisker Resources Ltd. is excited to share that promising outcomes have surfaced from its initial testing of ore sorting technologies at the Bralorne Gold Project. This flagship site, situated in British Columbia, is undergoing a revitalization aimed at enhancing gold recovery processes. The success of these technologies...

Continue Reading
Avalanche Experiences Significant Price Surge of 5.53% in One Day

Updated Category News Views 79

Avalanche Sees Impressive Market Performance Avalanche (AVAX) has demonstrated a remarkable surge in the cryptocurrency market, with its price climbing 5.53% in just 24 hours, now sitting at $29.11. This impressive rise is part of a larger trend, as the coin has seen a weekly increase of over 10%, up from $26.40. Notably, the coin has reached an all-time high of $144.96,...

Continue Reading